Cisplatin chemotherapeutic efficacy in cancer therapy is limited by its nephrotoxicity. Sitagliptin, an orally available dipeptidyl peptidase-4 (DPP-4) inhibitor developed to be used as a once daily treatment for type 2 diabetes mellitus (T2DM), and could attenuate diabetic nephropathy in rats. The renoprotective effect of sitagliptin was studied in cisplatin-induced nephrotoxicity in albino rats. Twenty four male albino rats were classified into 4 equal groups; 1st group which is normal control group, 2nd group involves rats with cisplatin-induced nephrotoxicity and receive no treatment, 3rdgroup involves rats receiving sitagliptin (10 mg/kg/day) for 6 weeks, and 4th group involves rats treated by sitagliptin (10 mg/kg/day) for 6 weeks before induction of nephrotoxicity by cisplatin. The current work revealed that treatment with oral sitagliptin in male albino rats before induction of nephrotoxicity by cisplatin resulted in a significant improvement of cisplatin-induced nephrotoxicity; evident by a significant (p100% & 17.9% respectively, compared to the untreated cisplatin group but these results still highly significant if compared to the control group. Also, there was a significant improvement of the histopathological examination of the kidney. Thus, sitagliptin can ameliorate nephrotoxicity induced by cisplatin |
